Eli Lilly's valuation is justified when you look at the growth profile, says UBS' Bristow

In this video

Share

Eli Lilly's valuation is justified when you look at the growth profile, says UBS' Bristow

Colin Bristow, UBS analyst, joins 'Closing Bell' to discuss the excitement around Eli Lilly's new diabetes drug, what goes into the $25 billion estimate that UBS has for the new drug and the company's current valuation.
03:42
Thu, Sep 22 20224:20 PM EDT